Avis Budget Group, Inc. (CAR)
Ethic Inc. Acquires New Position in Avis Budget Group, Inc. $CAR
Ethic Inc. acquired a new stake in shares of Avis Budget Group, Inc. (NASDAQ: CAR) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,894 shares of the business services provider's stock, valued at approximately $330,000. Several other
Hemogenyx shares rise after safety board backs next trial phase for CAR-T therapy
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares climbed as much as 8% in early trading after the biotech company said US regulators had cleared its experimental CAR-T therapy for leukaemia to move to a higher dose level in its ongoing Phase I trial. The independent Data Safety Monitoring Board, which oversees the study, reviewed safety data from the first three adult patients treated with Hemogenyx's HG-CT-1 therapy for relapsed or refractory acute myeloid leukaemia and found no dose-limiting toxicities.
Avis Budget Group (CAR) Q3 Earnings and Revenues Top Estimates
Avis Budget Group (CAR) came out with quarterly earnings of $10.11 per share, beating the Zacks Consensus Estimate of $8.11 per share. This compares to earnings of $6.65 per share a year ago.
Avis Budget Group Up 4% After Q3 Earnings: Here's Why
Avis Budget Group (NASDAQ: CAR) delivered a sharp earnings surprise on Monday after the close, posting $10.11 in adjusted EPS that crushed consensus expectations of $8.12.
Hemogenyx rises on progress in CAR-T trial
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares jumped 26% after the biotech reported encouraging early results from its phase I trial of HG-CT-1, an experimental CAR-T therapy for relapsed or refractory acute myeloid leukaemia (AML). The London-listed company said its third patient had been treated successfully, with the therapy meeting initial safety targets and showing signs of efficacy.
Avis Budget Stock Declines 22% Since Reporting Q2 Earnings Miss
CAR plunges 22% after second-quarter 2025 earnings and revenues miss estimates despite a nearly 98% YTD surge in shares.
Avis Budget Group, Inc. (CAR) Q2 2025 Earnings Call Transcript
Avis Budget Group, Inc. (NASDAQ:CAR ) Q2 2025 Earnings Conference Call July 30, 2025 8:30 AM ET Company Participants Brian J. Choi - Chief Executive Officer David T.
Avis Budget (CAR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Avis Budget (CAR) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Avis Budget Group (CAR) Misses Q2 Earnings and Revenue Estimates
Avis Budget Group (CAR) came out with quarterly earnings of $0.1 per share, missing the Zacks Consensus Estimate of $2.02 per share. This compares to earnings of $0.41 per share a year ago.
Waymo taps Avis to manage robotaxi fleet in Dallas
Waymo said it plans to launch a robotaxi service next year in Dallas, the latest city to be added to the Alphabet-owned company's growing commercial footprint that already includes Los Angeles and San Francisco.
Canadian Apartment REIT: More Upside After A Pause
We had upgraded Canadian Apartment REIT to a strong buy due to robust Q4 results and management's strategic actions. The stock has outperformed our shorter term expectations. We review the recent results and update our thesis.
Anixa Biosciences: Oncology Platform With Asymmetric Upside
ANIX has a dual-platform approach. It has an FSHR‑targeted CAR‑T program for ovarian cancer and an α‑lactalbumin breast cancer vaccine. Their Phase 1 CAR‑T showed reasonable safety, as one patient remains alive after 24 months. Others have also exceeded the four‑month median survival. This means ANIX could start testing even higher doses, which might be even more effective.
